Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827027 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2022008634 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
Expert Rev Hematol
December 2024
Clinical Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
Article Synopsis
- * The article examines the effectiveness of combining ibrutinib and venetoclax in treating relapsed or refractory MCL based on findings from two clinical studies: the AIM study, which involves a run-in period with ibrutinib, and the SYMPATICO study, which administers both drugs simultaneously.
- * It suggests that this combination therapy may be effective and could eventually allow for fixed-duration treatment; ongoing research into measurable residual disease may help determine which patients can safely stop treatment after
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Exp Hematol Oncol
March 2024
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Article Synopsis
- Mantle cell lymphoma (MCL) is a cancer characterized by uncontrolled cell growth, and researchers studied how well palbociclib, a CDK 4/6 inhibitor, works alone and with venetoclax, a BCL2 inhibitor, on MCL cells.
- They conducted experiments using both MCL cell lines and patient-derived models to evaluate the effectiveness, mechanisms, and potential markers that could indicate which patients might benefit from this combination therapy.
- The findings showed that the combination treatment was more effective than either drug alone, particularly for patients with MCL that does not have RB1 deletion, suggesting a promising approach to treating this type of lymphoma without traditional chemotherapy.
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.
Blood Res
December 2023
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Article Synopsis
- The study evaluated the effectiveness of ibrutinib for treating relapsed or refractory mantle cell lymphoma (MCL) in a group of 42 patients, showing a 69% overall response rate with notable survival outcomes.
- Key findings include a median progression-free survival of 16.4 months and overall survival of 50.1 months, but older patients and those with certain risk factors had worse outcomes.
- The study emphasizes the need to assess patient characteristics before using ibrutinib and suggests that early relapse indicates a need for new treatment options.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Blood Adv
January 2023
Division of Hematology, City of Hope, Duarte, CA.
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Adv Ther
October 2022
Eli Lilly Japan K.K, Kobe, Japan.
Introduction: Treatment options in patients with mantle cell lymphoma (MCL) failing ibrutinib are limited, with no standard therapies defined. This study aimed to investigate real-world treatment patterns and outcomes for patients with MCL following ibrutinib.
Methods: This study utilized a de-identified hospital-based claims database (Medical Data Vision) in Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!